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Abstract Based on an analysis of results taken from site-di- 
rected mutagenesis studies performed on opioid receptors, a role 
for the extracellular loops in conferring opioid subtype selectivity 
is proposed. It is suggested that the extracellular loop regions 
(which represent he region of highest sequence variability among 
opioid subtypes) interact with opioid ligands in a primarily non- 
specific fashion. Although these interactions are non-specific, 
they appear to play a discriminatory role in ligand binding and, 
in certain cases, prevent particular ligands from binding among 
receptor subtypes. We propose that selectivity may be imparted 
through a mechanism of exclusion, rather than specific pharma- 
cophore recognition within the extracellular loops and N-terminal 
domain. This hypothesis is supported by a careful analysis of the 
binding profiles of several selective and non-selective ligands to 
a variety of chimeric mutants. These results, when combined with 
results taken from single-point mutation experiments point to the 
existence of a high affinity binding pocket within the transmem- 
brane region which may be common among the opioid subtypes. 
Key words: Opioid receptor; Extracellular loops; Chimeric 
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1. Introduction 
Over the years, a great deal of effort has been devoted to 
understanding the structure-activity relationships of opioid li- 
gands, especially as they relate to selectivities among the known 
receptor subtypes (& fl, and x). Although binding data for a 
wide variety of peptide and non-peptide ligands has produced 
great insight to the basis for molecular ecognition, a detailed 
understanding of the structural requirements for ligand binding 
has not yet emerged. Using the 'message-address' concept of 
Schwyzer [1], Takemori and Portoghese have suggested ligand 
binding and selectivity may be conferred through the recogni- 
tion of two distinct structural units [2]. According to this con- 
cept, opioid ligands possess both an 'address' and a 'message' 
that play unique functional roles in ligand binding and receptor 
function. Although both elements are presumed to bind to the 
receptor, the address is thought o impart selectivity while the 
message is common. This concept is exemplified by the struc- 
tures of endogenous opioid peptides enkephalin and dynor- 
phin, where the N-terminal tyrosine residue may be considered 
the common message and the C-terminal domain presents the 
*Corresponding author. Fax: (1) (612) 626-4429. 
E-mail: ferguson@quinn.medc.umn.edu 
variable address. It has been proposed that the selectivity of 
dynorphin for x is conferred through the presence of several 
basic amino acid residues in the address [2]. This address, when 
appended to the C-terminus of the 6-selective nkephalin, has 
also been shown to increase the x affinity, lending some support 
to the generality of a subtype address [3]. 
Although this concept has been used to rationalize binding 
data for a number of opioid ligands, the absence of structural 
data relating the receptor and ligand has proven problematic 
in interpreting the results. The relatively recent cloning and 
sequencing of the opioid receptors, however, has begun to 
provide new insight o mechanism of ligand binding and recep- 
tor function [4~8]. Simple sequence analyses of the receptors 
has revealed that these proteins, as many G-protein coupled 
receptors, show very high sequence homology within the puta- 
tive transmembrane domain (for review see [9]), suggesting a 
common binding pocket among opioid subtypes. The extracel- 
lular loops and N-terminal domains, on the other hand, show 
limited sequence identity. While indirectly, these observations 
support he general hypothesis that the common 'message' of 
opioid ligands may bind within the transmembrane domain of 
the receptor. Furthermore, the extracellular loops which are 
different among subtypes may recognize the variable 'address', 
thereby imparting the selectivities known for various ligands. 
In order to isolate regions of the opioid receptor subtypes 
which play a role in selectivity, various studies involving chim- 
eric mutants which allow for the exchange of various extracel- 
lular loops among subtypes have been reported [3,10-16]. 
Chimeric mutants between all possible combinations (6/K, ~/fl, 
and x/~t) have been generated and in several studies, potential 
interactions between selective ligands and extracellular loop 
regions have been suggested [3,13,16]. In this report, we review 
the results of various chimeric studies performed on opioid 
receptors and interpret hem in combination with results in- 
volving single-point mutations. The analysis presented corre- 
lates the binding data of several opioid ligands across all mu- 
tant sequences to determine the role that the extracellular loops 
and the N-terminus play in ligand recognition. The results also 
emphasize the importance of sites of recognition in the trans- 
membrane domain that may be common among all subtypes. 
2. Binding of DAMGO as a prototype for an alternative opioid 
ligand-receptor interaction model 
The/1 selective peptide agonist, DAMGO ([o-Ala 2, MePhe 4, 
Gly(ol)5]enkephalin), has been the subject of several recent 
reports involving chimeric opioid receptors [10-13]. DAMGO 
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is highly selective for the At receptor, showing minimal affinity 
for ~ or K receptors (K~ > 1000 nM). [17]. In the first study, 
chimeric receptors are made which possess elements of fi and 
At receptors and the most striking results are shown for recep- 
tors in which the first extracellular loop is exchanged. In partic- 
ular, when the first extracellular loop (EL-l) from the ~ recep- 
tor is incorporated into the At receptor, DAMGO binding is 
significantly decreased. When the reciprocal chimeric receptor 
is constructed (EL-1 of At is incorporated into the ~ receptor) 
specific high affinity binding of DAMGO to the mutant recep- 
tor occurs [10]. Another study involving ~/At chimera identified 
EL-1 as playing a key role in conferring the At selectivity of 
DAMGO [11]. Based on these results, it is reasonable to suggest 
that EL-1 of the At receptor is involved in DAMGO binding. 
A third study compares the binding of At selective agonists 
(including DAMGO) to two K/At chimeras. Interestingly, it was 
found that a K/At chimera in which only helix 6, EL-3, helix 7, 
and the C-terminus were taken from the At receptor bound 
DAMGO with a K~ value of 11.8 nM whereas the native 
At receptor gave an affinity of 3.3 nM. The reciprocal chimera 
which possessed the latter portions of the K receptor bound 
DAMGO with a Ki value of 363 nM. The native x receptor 
showed no affinity for DAMGO [12]. Another study involving 
DAMGO binding to K/At chimera has identified the third ex- 
tracellular loop as the region of discrimination between At and 
K opioid receptors [13]. The results of these studies contrast 
sharply with the concept of specific high affinity contacts be- 
tween DAMGO and EL-1 of the At receptor. Rather than pro- 
viding specific ligand binding sites, it is possible that the ex- 
tracellular loops act via an exclusion mechanism whereby par- 
ticular elements of the loops have unfavorable interactions with 
selective ligands preventing binding. In the case of DAMGO, 
its At selectivity may be conferred by unfavorable interactions 
with the extracellular loops of ~ and K, rather than specific 
favorable contacts between DAMGO and the extracellular 
loops of m. This notion is in harmony with an opioid binding 
pocket wherein the 'message' portion of opioid ligands binds 
inside the receptor cavity formed by the 7 transmembrane (TM) 
domains which possess high sequence homology among the 
opioid receptor subtypes. In this view, the extracellular loop 
regions act as a barrier to the high affinity ligand binding region 
which resides in the transmembrane domain. 
This view is also supported by results of single-point site- 
directed mutagenesis studies on opioid receptors. An analysis 
of these results shows a trend that selective opioid ligands are 
more sensitive to point mutations in the transmembrane region 
than are non-selective ligands [18-20]. In other words, binding 
of selective ligands is typically reduced by such point mutations 
whereas non-selective ligands remain relatively unaffected. This 
is well demonstrated by DAMGO binding to the At receptor. 
Several studies have shown that single-point mutations of as- 
partate residues in TM 2 and 3 as well as the histidine in TM 
6 each cause dramatic decreases in DAMGO binding to the 
At receptor [19,21 ].Such results are not compatible with a model 
in which specific favorable interactions with the loop regions 
stabilize ligand binding and confer selectivity. However, if the 
path of the selective ligand to the receptor cavity is inhibited 
by the loops (as suggested in the above model) it is possible that 
this limits the possible orientations of the ligand in approach 
to the receptor cavity, making it highly dependent on favorable 
interactions found inside the ligand binding pocket. Thus, even 
though DAMGO binds the At receptor with high affinity, its 
path to the binding pocket inside the receptor may still be 
restricted by the extracellular loops such that loss of any bind- 
ing sites in the cavity via mutation would cause a significant 
decrease in ligand binding. 
By contrast, relatively non-selective opioid ligands, which 
tend to be small rigid molecules possessing the characteristic 
tyramine or 'message' moiety (e.g. ethyl ketocyclazocine, bre- 
mazocine, diprenorphine), give a much different binding profile 
to mutant receptors. In particular, several studies have demon- 
strated that these ligands bind virtually all chimeric receptors 
with affinities equal to that of wild type receptors [10-13,16]. 
This strongly suggests that high affinity binding is conferred in 
regions of the TM domains of the receptor egardless of the 
subtype (i.e. binding to residues conserved among receptor 
subtypes). The non-selectivity of these ligands is, in our view, 
due to their ability to essentially bypass the extracellular loops 
and enter into the transmembrane region. This lack of restric- 
tion of the loops on these ligands gives them more freedom of 
mobility which would make them less dependent on individual 
interactions in the ligand binding site. This additional freedom 
would explain their relative insensitivity to single-point muta- 
tions compared to selective ligands. 
3. Discussion 
Although the above conceptual model has been discussed 
with respect o only a single ligand, it was derived from an 
analysis of a variety of results. As such, we will now discuss its 
application to the interpretation of other site-directed mut- 
agenesis results performed on opioid receptors. Several reports 
involving chimeric receptors have focused attention on EL-2 of 
the K receptor as being important in determining the x selectiv- 
ity of dynorphin peptides [3,14~16]. One study using a At/K 
chimera in which EL-2 of the K receptor is inserted into the 
At receptor demonstrates a marked increase in affinity for a- 
neoendorphin, dynorphin A(1-13), and dynorphin A(1-17) 
[14]. A similar pattern of results emerged from a study of 
enkephalin and dynorphin fragments interacting with ~ and x 
receptors and four ~;/K chimeric receptors. This study empha- 
sized the role of coulombic interactions between the basic resi- 
dues of the dynorphin fragments and the acidic residues located 
on EL-2 of the x receptor [3]. These interactions appear to be 
crucial to conferring x selectivity since EL-2 of the x receptor 
possesses five acidic residues which are not found in 8 and At. 
Recently, amore comprehensive study of the molecular basis 
of affinity and selectivity between ~ and x receptors has ap- 
peared which examines the binding of various selective and 
non-selective, peptide and non-peptide, agonist and antagonist 
opioid ligands to 6, K, and 5/K chimeric receptors [15]. Some 
of the most interesting results from this study regard the selec- 
tivity of enkephalin and dynorphin to ~ and x receptors. In 
particular, dynorphin A(1-13) shows high affinity for both wild 
type receptors (Ki values of 8.7nM and 0.9 nM for ~ and x 
respectively) while the enkephalins are very t~ selective (3.4 nM 
and >10000 nM for Met-enkephalin, 2.2 nM and 1300 nM for 
Leu-enkephalin). Analysis of the binding studies on chimeric 
receptors indicates enkephalins bind with reasonable affinity to 
chimera having only the C-terminal portion (helices 5, 6, 7, their 
interconnecting loops, and the C-terminus) from the fi receptor. 
To explain these results, it has been suggested that the ~ reeep- 
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tor contains a high affinity binding pocket for the 'opioid core' 
(defined as Tyr-Gly-Gly-Phe) in the C-terminal domain capable 
of binding both enkephalins and dynorphin. This pocket is then 
said to be relatively weak in the x receptor and the binding of 
dynorphin to x is dependent on the coulombic interactions 
between the basic residues of the peptide and the anionic resi- 
dues found in EL-2 of the x receptor [15]. 
According to our conceptual model given above these results 
can be explained in an alternative fashion. For example, it is 
possible that unfavorable interactions between enkephalins and 
extracellular loop 3 of the x receptor prevent enkephalin bind- 
ing to the x receptor. The sequences of helices 5, 6, and 7 of 
the 8 and x opioid receptors are very highly homologous. Thus, 
the enkephalin binding of the x/8 chimera possessing the latter 
portion of the ~ receptor isvery likely due to differences in EL-3 
between x and 8 where there is limited sequence homology. 
Furthermore, in our interpretation, it is not evident hat x and 
bind the opioid core differently. As stated above, the high 
homology among opioid receptor subtypes in the transmem- 
brane region suggests a common binding pocket for common 
structural elements found in opioid ligands. If enkephalin bind- 
ing to the x receptor is indeed prevented by EL-3 of x then it 
is very possible that the pocket in x is very similar to that of 
6. Mutational studies performed on opiate receptors to date 
have provided no powerful evidence that the tyramine moiety 
of small non-selective ligands binds in a different manner than 
the N-terminal tyrosine of peptide ligands regardless of the 
receptor subtype. 
With respect o the importance of coulombic interactions 
between dynorphin and anionic residues on EL-2 of the x 
receptor, two points should be raised. First, although dynor- 
phin possesses highest affinity for x receptors, it has been 
shown to have K~ values in the nanomolar range for both ~ and 
p [14,15]. This demonstrates that interactions between the C- 
terminal end of dynorphin and the anionic residues found on 
EL-2 of x are not required for opioid binding. Secondly, muta- 
tion of the aspartate residue in helix 3 of the x receptor causes 
a 600-fold decrease in dynorphin binding (T. Reisine, unpub- 
lished results). This again emphasizes the importance of trans- 
membrane regions in ligand binding and casts some doubt on 
the importance of the contribution of the proposed coulombic 
interactions in dynorphin binding to the x receptor. 
An analysis of the results of 8/x and/z/x chimera highlights 
the putative role of extracellular loop 3 of the x receptor in 
preventing the binding of both 8 and p selective ligands to the 
x receptor. In order to understand the 8lx selectivity of en- 
dogenous opioid peptides, it is perhaps more useful to investi- 
gate why enkephalins do not bind to the x receptor rather than 
why dynorphin does since both peptides appear to bind the 
receptor with high affinity [15]. A chimeric receptor possess- 
ing the N-terminus, EL-l, and EL-2 from the 8 receptor and 
EL-3 from the x receptor showed minimal, if any, affinity for 
enkephalins as well as other 8 selective peptides. Importantly, 
the reciprocal chimera, in which x/EL-3 is absent, showed 
markedly increased affinities for 8 selective peptides even 
though the majority of the chimeric construct is from the x 
receptor [15]. It is apparent that the presence of EL-3 from the 
x receptor is sufficient o inhibit the binding of the 8 selective 
peptides. Results from II/X are similar. In the p/x case, it has 
been shown the presence of EL-3 from x (in a chimera with the 
N-terminus, EL-1 and EL-2 from the/1 receptor) gives notable 
decreases in binding affinity for p-selective ligands DAMGO, 
PLO17, sufentanil, and morphine [12]. As indicated above, 
results from H/d chimera have shown that EL-3 of the p recep- 
tor is not required for specific, high affinity binding of 
DAMGO thus supporting the exclusionary effect of x/EL-3 
[10,11]. 
Another class of opioid ligands that displays an interesting 
pattern of site-directed mutagenesis results is that of the x 
selective arylacetamides such as U50,488. A set of six p/x chi- 
mera was generated and the binding of arylacetamides U50,488 
and U69,593 was tested across each chimera s well as the wild 
type ~ and x) receptors [16]. It was found that the incorpora- 
tion of EL-2 of the x receptor into the p receptor gave x-like 
binding of opioid peptides uch as dynorphin A and B, and 
a-neo-endorphin (as had been shown previously [14]). By con- 
trast, U50,488 and U69,593 did not bind this chimera. The 
arylacetamides did show high affinity binding for the reciprocal 
chimera in which EL-2 of the p receptor was inserted into the 
x receptor. Interestingly, another pair of reciprocal chimera 
was generated in which neither receptor showed affinity for 
U50,488 and U69,593. The authors of this study concluded that 
U50,488 and U69,593 appear to require the whole x receptor 
except EL-2 to attain high affinity binding. In a study of 5/x 
chimera, it was found that a chimeric mutant possessing the 
C-terminal portion (from helix 5 to the C-terminus) of the 
receptor could bind U50,488 with affinities very similar to that 
of the x wild type. Other ~/x chimera showed ecreased binding 
for U50,488 relative to the wild type x receptor [15]. 
These results, when interpreted within our conceptual frame- 
work, are consistent with several aspects mentioned previously. 
It is possible that the extracellular loops of ~ and H prevent 
binding of arylacetamides to the transmembrane r gion and 
that this is the basis of their high x selectivity. The fact that 
U50,488 shows no affinity (Ki>10,000 nM) for four of six II/x 
chimeric receptors [16] is consistent with the idea that the ex- 
tracellular loops of the x receptor do not possess binding deter- 
minants pecific for this ligand. Apparently, the loops of the x 
receptor present a barrier insufficient o prevent binding of 
arylacetamides to the receptor yet they provide enough of a 
barrier to make binding highly dependent on favorable interac- 
tions in the binding pocket. Such dependence is evidenced by 
the dramatic decreases in binding of U50,488 and U69,593 
upon mutation of aspartate residues in helices 2 and 3 of the 
x receptor ([20]; T. Reisine, unpublished results). 
It is noteworthy that in each of the studies discussed above 
the ligands involved are agonists. This obviously raises ques- 
tions pertaining to antagonist binding. Of course, it is unlikely 
that antagonists bind to opioid receptors in a fashion identical 
to that of agonists ince agonists can effect G-protein coupling 
while antagonists do not. The opioid antagonist naloxone has 
been shown to bind all three opioid receptor subtypes with 
relatively high affinity (K i of 17 nM, 2.3 nM and 0.93 nM for 
6, x and,u respectively) [17]. Similarly, naloxone binds to chim- 
eric receptors with affinities similar to that of wild type recep- 
tors [14,15]. Also, naloxone binding to the ~t receptor can be 
reduced by single-point mutations in the transmembrane region 
[21]. These results uggest that opioid binding of naloxone must 
be largely conferred by regions of the transmembrane domain 
common to opioid receptor subtypes imilar (but not identical) 
to the non-selective agonists discussed above. The binding of 
selective antagonists o chimeric receptors has been much less 
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well studied than that of agonists. From the studies that have 
been done, it is found that selective antagonists have somewhat 
different binding profiles to chimeric receptors than their ag- 
onist counterparts [12,15,16]. For example, the x selective an- 
tagonist, norbinaltorphimine, binds in a different manner to ~/x 
and ¢t/x chimera than do the x selective arylacetamide agonists 
[15,16]. It has been noted that it is not clear if this is due to their 
difference in structure (arylacetamide v rsus alkaloid dimer) or 
function (agonist versus antagonist) [15]. In light of the lack 
studies performed on antagonists o date, it is not clear if or 
how the concepts outlined above apply to selective antagonists. 
4. Summary and conclusion 
In this report, a conceptual model for opioid selectivity based 
on the interpretation of results of single-point and chimeric 
mutations of opioid receptors has been presented. According 
to our analysis, we hypothesize that the extracellular loops of 
opioid receptors confer selectivity primarily by a mechanism of 
exclusion. This is not to say that favorable interactions between 
opioid ligands and receptor extracellular loops do not occur. 
Undoubtedly, such interactions do occur and play some role 
in ligand recognition and specificity. However, the results of the 
various mutation experiments performed to date have not dem- 
onstrated the existence of a specific, high affinity binding site 
on the extracellular loops. Indeed, analysis of some particular 
cases provides strong evidence toward the exclusion of this 
possibility. 
Our proposal for the basis of opioid selectivity also has 
important consequences for ligand design. It is difficult to ra- 
tionally design a selective ligand if there is no particular 'ad- 
dress' binding site that confers specificity to a given receptor. 
For example, highly selective ligands such as DAMGO and 
U50,488 do not appear to have high affinity binding sites on 
receptor loops. To understand specific ligand-receptor interac- 
tions, it may be as useful to assess which elements of the 'ad- 
dress' moiety prevent binding to a particular receptor subtype 
as it is to look for receptor sites that enhance binding. Again, 
our analysis does not exclude the possibility of 'address' bind- 
ing subsites on particular eceptors. It has been noted previ- 
ously that selectivity can be conferred by enhanced binding as 
well as prevention of binding to a given subtype [2]. The site- 
directed mutagenesis studies performed to this point, however, 
emphasize the importance of an exclusion mechanism. 
In a broad sense, it is possible that the role of the extracellu- 
lar loops of opioid receptors i to exclude binding of ligands to 
the relatively promiscuous binding site located within the trans- 
membrane domain. In its simplest form, opioid receptor bind- 
ing would involve binding of the tyramine moiety of opioid 
ligands to a pocket formed by the transmembrane h lices. This 
pocket may be common to all opioid receptor subtypes. Selec- 
tivity is conferred by the interplay between the ligand and the 
extracellular loops as the ligand attempts to get its 'message' 
to the binding pocket. The extracellular loops thus act as a gate 
which allows for the passage of certain ligands while excluding 
others. While this model is very likely overly simplified, it is 
consistent with our analysis of results taken from site-directed 
mutagenesis experiments on opioid receptors. In addition, this 
hypothesis i further supported by the following fundamental 
observations. First is the existence of relatively non-selective 
opioid ligands such as bremazocine and ethylketocyclazocine. 
These ligands tend to be small and rigid enabling them to more 
easily bypass extracellular loops than bulkier ligands. Also, 
they possess the critical tyramine moiety which most likely 
binds in the receptor cavity. This is demonstrated by the fact 
that these ligands bind virtually all chimeric receptors with 
equal affinity. Second, the high sequence identity of transmem- 
brane regions among opioid receptor subtypes i  suggestive of 
a common binding site within this region. Although it has by 
no means been demonstrated, there is, as yet, no convincing 
evidence that the common elements of opioid ligands do not 
bind elements common among the opioid receptor subtypes in 
the transmembrane domain. Studies involving single-point mu- 
tations of residues in the transmembrane domain of opioid 
receptors would be instrumental in learning more about this 
binding site. 
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